CALCR binds erenumab

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Therapeutic agents that block the calcitonin gene-related peptide (CALCA, CGRP) signaling pathway are efficacious for both acute migraine treatment and migraine prevention. Erenumab (AMG 334) is a fully human monoclonal antibody against the CGRP receptor (CALCR) that competes with CALCA binding to human CALCR, inhibiting CALCA-stimulated cAMP production (Shi et al. 2016). In studies of efficacy of erenumab in patients with episodic migraine, it provided sustained efficacy in episodic migraine with good tolerability (Goadsby et al. 2020, Broessner et al. 2020).
Literature References
PubMed ID Title Journal Year
32851644 The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

Hallström, Y, Bonner, JH, Reuter, U, Picard, H, Broessner, G, Mikol, DD, Dodick, DW, Klatt, J, Lenz, RA, Zhang, F

Headache 2020
32636324 One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study

Hallström, Y, Goadsby, PJ, Bonner, JH, Reuter, U, Picard, H, Broessner, G, Mikol, DD, Lenz, RA, Klatt, J, Wright, IK, Chou, DE, Zhang, F

Neurology 2020
26559125 Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

Lehto, SG, Xu, C, Sun, H, Zhang, J, Smith, BP, Immke, DC, Wild, KD, Zhu, DX, Shi, L

J. Pharmacol. Exp. Ther. 2016
Orthologous Events
Cite Us!